Denileukin
Definition
Denileukin (denileukin difitox) is a fusion protein, or a protein made from two different proteins, that is used to treat recurrent cutaneous T-cell lymphoma.
Purpose
Cutaneous T-cell lymphoma (CTCL)is a form of non-Hodgkin's lymphoma, or an uncontrolled growth of cells in the lymph system that begins in the skin. It may spread to other organs.
Denileukin is known by the full name denileukin difitox, and also by the brand name Ontak. It causes the death of T cells or lymphocytes that are being made in enormous numbers by tricking the troublesome cells into binding with it, and then killing them.
Description
Denileukin is a genetically engineered protein, created by fusing a piece of the toxin that causes diphtheria with interleukin-2 (also known as IL-2 or aldesleukin). Because of the presence of IL-2 in the fusion protein denileukin, cells that have IL-2 receptors bind with it. Thus, the cells are fooled into binding with a protein they recognize, only to be killed by the toxin that is fused with it.
Not all malignant T cells and lymphocytes have IL-2 receptors. If the cells do not have the receptors, denileukin is not useful.
Recommended dosage
Denileukin is given through intravenous line. The best therapy course has not yet been determined. But the standard dose is either 9 or 18 micrograms per kilogram of body weight per day for five consecutive days, every three weeks.
Precautions
Because the use of the treatment can contribute to an environment that encourages infections, largely because
Oncologists using the treatment must first test the cells of the patient for receptivity to IL-2. The treatment should not be used in patients that do not have the specific receptors for IL-2 that tricks the cells into binding with denileukin. The receptors of the cells that will bind all have a component known as CD25.
About 60% of patients diagnosed with CTCL have the receptors for IL-2. The Food and Drug Administration (FDA) has approved denileukin for use in patients that have not responded to other treatments.
